Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.4
5.2
Journals
Cancers
Special Issues
Clinical Trials in Skin Cancers
share announcement

Clinical Trials in Skin Cancers

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Clinical Research of Cancer".

Deadline for manuscript submissions: closed (1 March 2023) | Viewed by 4922

Special Issue Editor

Dr. Yoshiyuki Nakamura

E-Mail Website
Guest Editor
Departments of Dermatology, Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki 305-8575, Japan
Interests: melanoma; surgery; skin cancer

Special Issue Information

Dear Colleagues, 

The treatment of skin cancer has significantly developed over the last few years. Immune checkpoint inhibitors and BRAF/ MEK inhibitors have been shown by previous prospective studies to improve the prognosis of melanoma patients. Immune checkpoint inhibitors have also been shown to improve other skin cancer such as Merkel cell carcinoma. The efficacy and safety of the treatment shown in the prospective studies were supported by real world data. In addition, clinical trials also revealed improved surgical method for skin cancer.

This Special Issue will highlight the clinical trial or clinical studies of skin cancer including cutaneous lymphoma and potential future prospects. Manuscripts are welcome that report clinical trial or clinical studies on original or updated data, including retrospective observational studies, and comprehensive literature reviews of clinical trial of skin cancer. This Special Issue especially focuses on checkpoint inhibitors and/or targeted therapy in patients with skin cancer, and surgical methods including surgical approaches for regional lymph nodes and reconstructive surgeries. Other topics may also be of interest and will be considered.

Dr. Yoshiyuki Nakamura
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • clinical trial
  • skin cancer
  • dermatology
  • surgery
  • prognosis

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

17 pages, 664 KiB  
Review
The Current State of Neoadjuvant Therapy in Resectable Advanced Stage Melanoma
by Omar Bushara, Jerica Tidwell, James R. Wester and John Miura
Cancers 2023, 15(13), 3344; https://0-doi-org.brum.beds.ac.uk/10.3390/cancers15133344 - 26 Jun 2023
Cited by 1 | Viewed by 1396
Abstract
The advent of effective immunotherapy and targeted therapy has significantly improved outcomes in advanced-stage resectable melanoma. Currently, the mainstay of treatment of malignant melanoma is surgery followed by adjuvant systemic therapies. However, recent studies have shown a potential role for neoadjuvant therapy in [...] Read more.
The advent of effective immunotherapy and targeted therapy has significantly improved outcomes in advanced-stage resectable melanoma. Currently, the mainstay of treatment of malignant melanoma is surgery followed by adjuvant systemic therapies. However, recent studies have shown a potential role for neoadjuvant therapy in the treatment of advanced-stage resectable melanoma. Mechanistically, neoadjuvant immunotherapy may yield a more robust response than adjuvant immunotherapy, as the primary tumor serves as an antigen in this setting rather than only micrometastatic disease after the index procedure. Additionally, targeted therapy has been shown to yield effective neoadjuvant cytoreduction, and oncolytic viruses may also increase the immunogenicity of primary tumors. Effective neoadjuvant therapy may serve to decrease tumor size and thus reduce the extent of required surgery and thus morbidity. It also allows for assessment of pathologic response, facilitating prognostication as well as tailoring future therapy. The current literature consistently supports that neoadjuvant therapy, even as little as one dose, is associated with improved outcomes and is well-tolerated. Some patients with a complete pathological response may even avoid surgery completely. These results challenge the current paradigm of a surgery-first approach and provide further evidence supporting neoadjuvant therapy in advanced-stage resectable melanoma. Further research into the optimal treatment schedule and dose timing is warranted, as is the continued investigation of novel therapies and combinations of therapies. Full article
(This article belongs to the Special Issue Clinical Trials in Skin Cancers)
►▼ Show Figures

Figure 1

19 pages, 375 KiB  
Review
Role of Sentinel Lymph Node Biopsy for Skin Cancer Based on Clinical Studies
by Shoichiro Ishizuki and Yoshiyuki Nakamura
Cancers 2023, 15(13), 3291; https://0-doi-org.brum.beds.ac.uk/10.3390/cancers15133291 - 22 Jun 2023
Cited by 1 | Viewed by 1174
Abstract
The sentinel lymph node is the first lymph node from the primary tumor. Sentinel lymph node biopsy (SLNB) is a surgical procedure that can detect occult nodal metastasis with relatively low morbidity. It may also have a therapeutic effect via regional disease control. [...] Read more.
The sentinel lymph node is the first lymph node from the primary tumor. Sentinel lymph node biopsy (SLNB) is a surgical procedure that can detect occult nodal metastasis with relatively low morbidity. It may also have a therapeutic effect via regional disease control. The Multicenter Selective Lymphadenectomy-I (MSLT-I) trial revealed a prognostic benefit from SLNB in melanoma patients. However, it remains unclear whether there is a prognostic benefit from SLNB in patients with nonmelanoma skin cancer owing to a lack of randomized prospective studies. Nevertheless, SLNB provides important information about nodal status, which is one of the strongest factors to predict prognosis and may guide additional nodal treatment. Currently, SLNB is widely used in the management of not only patients with melanoma but also those with nonmelanoma skin cancer. However, the utilization and outcomes of SLNB differ among skin cancers. In addition, SLNB is not recommended for routine use in all patients with skin cancer. In this review, we provide a summary of the role of SLNB and of the indications for SLNB in each skin cancer based on previously published articles. Full article
(This article belongs to the Special Issue Clinical Trials in Skin Cancers)
27 pages, 442 KiB  
Review
Evidence from Clinical Studies Related to Dermatologic Surgeries for Skin Cancer
by Shoichiro Ishizuki and Yoshiyuki Nakamura
Cancers 2022, 14(15), 3835; https://0-doi-org.brum.beds.ac.uk/10.3390/cancers14153835 - 08 Aug 2022
Cited by 3 | Viewed by 1965
Abstract
Despite the significant progress made in the past several years in pharmacotherapies for skin cancer, such as BRAF/MEK inhibitors, immune checkpoint inhibitors, and Hedgehog pathway inhibitors, surgical removal of primary skin cancer is still the first choice of treatment unless distant metastases are [...] Read more.
Despite the significant progress made in the past several years in pharmacotherapies for skin cancer, such as BRAF/MEK inhibitors, immune checkpoint inhibitors, and Hedgehog pathway inhibitors, surgical removal of primary skin cancer is still the first choice of treatment unless distant metastases are evident. In cases of lymph node metastases with clinically palpable lymphadenopathy, lymph node dissection (LND) is typically performed for most skin cancers. In the surgical treatment of primary skin tumors, the surgical margin is critical not only for reducing the possibility of tumor recurrence but also for minimizing the cosmetic and functional complications associated with wide local excision. In contrast, dermatologic surgery can cause various complications. Although skin graft is frequently used for reconstruction of the surgical defect, extensive graft necrosis may develop if optimal stabilization of the graft is not obtained. LND also sometimes causes complications such as intraoperative or postoperative bleeding and postoperative lymphoceles. Moreover, as in other types of surgery, surgical site infection, intraoperative anxiety, and intraoperative and postoperative pain may also develop. These complications are frequently associated with significant morbidity and discomfort. In this review, we summarize the evidence from previous clinical studies regarding the optimal surgical margin for skin cancer and the methods for diminishing the complications associated with dermatologic surgery. Full article
(This article belongs to the Special Issue Clinical Trials in Skin Cancers)
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop